New developments in acne treatment: role of combination adapalene–benzoylperoxide

Abstract

The fixed-dose combination adapalene 0.1%/benzoylperoxide 2.5% (A/BPO) was introduced as an acne vulgaris therapeutic in 2007. It combines anti-inflammatory, keratolytic, comedolytic, and antibacterial properties. Thus, it addresses several pathophysiological factors involved in the pathophysiology of acne. This review highlights the rationale for the use of this fixed-dose combination product, its therapeutic efficacy including effects on adherence and quality of life, its use for different forms of acne, and the side-effect profile. In summary, the fixed-dose combination of A/BPO gel can be regarded as a highly effective and safe formulation. It is not associated with antibiotic resistance. It reduces factors that cause nonadherence and has positive effects on the quality of life of affected patients. The tolerance is good. The initial mild irritation potential can be addressed by adequate counseling. A/BPO can be used for all forms of inflammatory acne, including severe forms, as part of a combination with systemic antibiotics. Finally, it can also be used for the long-term treatment of chronic acne. Thus, it is a very valuable therapeutic option in daily practice, which is reflected by its strong recommendation in the “European S3-guidelines”.

A Prospective, Randomised, Controlled, Split-Face Clinical Trial to Assess the Safety and the Efficacy of Cold Atmospheric Plasma in the Treatment of Acne Vulgaris

“…The effect against non-inflammatory acne lesions was smaller with −14.9% versus −6.3% after placebo. For topical acne treatments, the reduction in inflammatory lesions after twelve weeks of therapy ranges from −44% to −72% for BPO, from −46 to −57% for adapalene, and from −62% to −70% for a combination of BPO and adapalene [43]. With a mean reduction in inflammatory acne lesions of about −50% after a study period of ten to twelve weeks, CAP seems to be slightly less effective than conventional topical treatments but shows much better skin tolerability.…”

Medicina alternativa à base de plantas medicinais no tratamento da acne

“…Nos casos mais graves de acne os medicamentos comumente empregados são os antibióticos sistêmicos, terapias hormonais e o uso da Isotretinoína oral (Brasil, 2015). Os antibióticos tópicos que são utilizados nos casos de acne leve a moderada, atuam sobre a acne inflamatória pela sua ação antimicrobiana sobre o C. acnes e são utilizados em associação com outras categorias de ativos, como associados com os retinóides tópicos e o peróxido de benzoíla em maior proporção (Kim & Ochsendorf, 2016;Leyden, 2003;Williams, Dellavalle, & Garner, 2012). Todos os antibióticos de uso tópico apresentam potencial irritação local, entretanto menos significativos comparados aos antibióticos sistêmicos (Leyden, 2003).…”

Current treatments of acne: Medications, lights, lasers, and a novel 650‐μs 1064‐nm Nd: YAG laser

“…In response to these recommendations, the use of fixed‐dose adapalene in combination with BPO has been explored recently in 2,780 young adults and adolescents with moderate inflammatory acne, 73 Brazilian patients with papular‐pustular acne, more than 2,300 patients with inflammatory and noninflammatory lesions by meta‐analysis, and 503 patients with moderate and severe acne in 31 centers . Advantages of this fixed‐dose combination are that it is efficacious, well tolerated, useful in all forms of acne, not associated with antibiotic resistance, improves quality of life, reduces factors associated with adherence, and can be used for long‐term treatment of chronic acne …”

“…27 Advantages of this fixed-dose combination are that it is efficacious, well tolerated, useful in all forms of acne, not associated with antibiotic resistance, improves quality of life, reduces factors associated with adherence, and can be used for long-term treatment of chronic acne. 28 The use of a fixed-dose combination of clindamycin (rather than adapalene) and BPO has also been explored in 498 patients with moderate to severe acne, 29 800 Japanese patients with inflammatory and noninflammatory lesions, 30 498 males vs. females with moderate to severe acne, 31 72 adult females with moderate to severe acne, 32 298 adolescents with moderate to severe acne, 33 and 498 patients with moderate to severe acne. 34,35 The combination is well tolerated and particularly useful in adult females, adolescents, and other populations with moderately severe disease.…”